ASCO 2024: Osimertinib After Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
Posted: 06/26/2024 | By: Sarah Campen, PharmD

The phase III LAURA study assessed the efficacy and safety of osimertinib in patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC) without disease progression after definitive chemoradiotherapy. Results were presented by Ramalingam et al at the 2024 ASCO Annual Meeting ((Abstract LBA4).).

Question 1 of 5

Which best describes osimertinib?

Choose 1